DexCom, Inc. (NASDAQ:DXCM) Shares Purchased by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC grew its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 4.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,750 shares of the medical device company’s stock after acquiring an additional 115 shares during the period. Nisa Investment Advisors LLC’s holdings in DexCom were worth $412,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Blair William & Co. IL lifted its position in shares of DexCom by 4.6% during the 1st quarter. Blair William & Co. IL now owns 1,010,355 shares of the medical device company’s stock valued at $120,333,000 after acquiring an additional 44,803 shares during the period. Virginia Retirement Systems ET AL increased its stake in shares of DexCom by 230.6% during the 1st quarter. Virginia Retirement Systems ET AL now owns 16,200 shares of the medical device company’s stock worth $1,929,000 after purchasing an additional 11,300 shares in the last quarter. Robeco Institutional Asset Management B.V. increased its stake in shares of DexCom by 32.0% during the 1st quarter. Robeco Institutional Asset Management B.V. now owns 162,127 shares of the medical device company’s stock worth $19,307,000 after purchasing an additional 39,300 shares in the last quarter. Allstate Corp purchased a new position in shares of DexCom during the 1st quarter worth approximately $247,000. Finally, American Century Companies Inc. purchased a new position in shares of DexCom during the 4th quarter worth approximately $13,436,000. Institutional investors own 96.21% of the company’s stock.

In related news, EVP Richard Doubleday sold 2,016 shares of DexCom stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $153.56, for a total transaction of $309,576.96. Following the transaction, the executive vice president now owns 72,570 shares in the company, valued at approximately $11,143,849.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Patrick Michael Murphy sold 400 shares of the business’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $116.92, for a total transaction of $46,768.00. The disclosure for this sale can be found here. Insiders have sold a total of 63,065 shares of company stock worth $8,207,313 in the last 90 days. Company insiders own 0.88% of the company’s stock.

Shares of NASDAQ:DXCM traded down $3.28 during midday trading on Monday, hitting $140.93. 8,966 shares of the company’s stock traded hands, compared to its average volume of 853,906. The company has a current ratio of 6.05, a quick ratio of 6.75 and a debt-to-equity ratio of 1.56. The firm has a market capitalization of $13.15 billion, a P/E ratio of 468.67 and a beta of 0.80. The firm has a fifty day moving average price of $149.93. DexCom, Inc. has a twelve month low of $105.05 and a twelve month high of $161.30.

DexCom (NASDAQ:DXCM) last posted its earnings results on Wednesday, July 31st. The medical device company reported $0.08 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.01 by $0.07. The business had revenue of $336.40 million for the quarter, compared to analyst estimates of $304.40 million. DexCom had a negative net margin of 13.96% and a positive return on equity of 10.41%. The business’s quarterly revenue was up 38.7% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.10) EPS. On average, equities research analysts forecast that DexCom, Inc. will post 0.94 EPS for the current fiscal year.

A number of research analysts have recently weighed in on DXCM shares. Oppenheimer raised their price objective on shares of DexCom from $167.00 to $180.00 in a research note on Thursday. TheStreet raised shares of DexCom from a “d+” rating to a “c” rating in a research note on Friday, June 28th. Piper Jaffray Companies raised their price objective on shares of DexCom from $173.00 to $182.00 and gave the stock a “positive” rating in a research note on Wednesday, July 31st. Robert W. Baird raised their price objective on shares of DexCom from $180.00 to $186.00 and gave the stock an “outperform” rating in a research note on Thursday. Finally, JPMorgan Chase & Co. raised their price objective on shares of DexCom from $170.00 to $190.00 and gave the stock an “overweight” rating in a research note on Thursday. Five investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $163.71.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

See Also: How is the Producer Price Index calculated?

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.